Targeting BRAF, with the small selective molecule inhibitors vemurafenib (V), dabrafenib (D), and encorafenib (E), showed clinical efficacy and improved survival outcomes in untreated BRAFV600 metastatic melanomas (MM) compared to standard chemotherapy [9,10,11,12]. This evidence concerns the gene BRAF and Miyoshi myopathy.